Language

News topic

Active ingredient INFLIXIMAB

Current shortage notices for the active ingredient INFLIXIMAB, structured by product, country and reporting period.

5 notices

← All shortages

What the INFLIXIMAB notices indicate for the supply chain

The 5 consolidated notices from Belgium, Austria are market and supply signals. They do not confirm current Inter-Pharma stock or a general ability to supply. Operational assessment requires separate verification of product status, batch, expiry, temperature requirements, recipient authorisation and the permitted distribution route.

GDP-capable pharmaceutical storage in Cheb

Inter-Pharma supports manufacturers, wholesalers and logistics partners with GDP-capable pharmaceutical storage in Czechia. Its own Cheb site enables project-specific buffer and safety stocks, batch and expiry control, FEFO, stock-status management, picking and dispatch preparation for Germany and Europe.

Belgium

Remsima 120 mg (Orifarm) inj. sol. s.c. pre-filled syr. 6 x 1 ml

Active ingredient: Infliximab

View notice details →
Belgium

Remsima 120 mg (Orifarm) inj. sol. s.c. pre-filled pen 2 x 1 ml

Active ingredient: Infliximab

View notice details →
Belgium

Remsima 120 mg (Orifarm) inj. sol. s.c. pre-filled pen 6 x 1 ml

Active ingredient: Infliximab

View notice details →
Austria

Remsima 100 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung

Active ingredient: INFLIXIMAB

View notice details →
Austria

Remsima 120 mg Injektionslösung im Fertigpen

Active ingredient: INFLIXIMAB

View notice details →

Plan supply. Connect sourcing and warehousing.

For pharmacies, wholesalers and manufacturers: choose the service matching your operational need.